T1	Participants 58 100	women with locally advanced breast cancer:
T2	Participants 248 276	patients with breast cancer.
T3	Participants 415 456	women undergoing neoadjuvant chemotherapy
T4	Participants 616 865	Eligible patients had clinical stage II-III (> or = T2 and/or > or = N1) newly diagnosed breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, and normal cardiac, renal, and liver function. 120 women were randomly assigned,
T5	Participants 1460 1585	120 patients initially enrolled, one withdrew after signing consent and one patient's baseline bone marrow was not available.